Cybersecurity Firms Gain Three-Tier Access to Anthropic’s Claude Mythos and Latest ModelsOctober 7, 2026
How Professional Crypto Traders Use Multiple Exchanges to Arbitrage Execution, Not Just PriceJune 1, 2026
Stock XPeng (XPEV) Stock Surges 6% Following Morgan Stanley’s Autonomous Driving System ReviewBy Ken CareyMarch 9, 2026
Stock NUBURU, Inc. (BURU) stock: slides as company unveils portable laser counter-drone defense systemBy Yasmin WernerMarch 9, 2026
Stock Newmont (NEM) Stock Soars on Major Price Target Hikes from Top AnalystsBy Ken CareyMarch 9, 2026
Stock Delta Air Lines (DAL) Stock Drops as TD Cowen Slashes Price Target Amid Fuel Cost WorriesBy Ken CareyMarch 9, 2026
Stock BitMine (BMNR) Ramps Up Ethereum Accumulation as Chairman Signals Market BottomBy Ken CareyMarch 9, 2026
Stock Apple (AAPL) Stock: Why Wall Street Remains Bullish Despite DRAM Price SurgeBy Ken CareyMarch 9, 2026
Stock Autozi Internet (AZI) Stock Soars 108% on $110 Million Investment ProposalBy Ken CareyMarch 9, 2026
Stock Unusual Machines (UMAC) Stock Surges 10% on Strong Revenue Performance in 2025By Ken CareyMarch 9, 2026
Stock Ondas Holdings (ONDS) Stock Skyrockets After Mistral Inc. Defense Merger AgreementBy Ken CareyMarch 9, 2026
Stock Nvidia (NVDA) Stock Drops 3% Amid Middle East Turmoil and Chip Supply ConcernsBy Ken CareyMarch 9, 2026
Stock Crude Oil Surges Past $100 Amid Iran Crisis, Triggering Sharp Stock Market SelloffBy Ken CareyMarch 9, 2026
Stock Microsoft (MSFT) Stock Drops 15% YTD as Copilot Cowork with Anthropic Claude DebutsBy Ken CareyMarch 9, 2026
Stock uniQure (QURE) Stock Jumps 36% Following FDA Director Prasad’s Exit AnnouncementBy Ken CareyMarch 9, 2026
Stock Xenon Pharmaceuticals (XENE) Stock Rockets 40% After Epilepsy Drug Trial Crushes GoalsBy Ken CareyMarch 9, 2026
Stock Relmada Therapeutics (RLMD) Stock Jumps 31% on Promising Bladder Cancer DataBy Ken CareyMarch 9, 2026
Stock Aureus Greenway (AUGS) Stock Jumps 55% Following Trump-Linked Drone Company Merger AnnouncementBy Ken CareyMarch 9, 2026
Stock Olema Pharmaceuticals (OLMA) Stock Plunges 41% Following Roche’s Failed Breast Cancer StudyBy Ken CareyMarch 9, 2026
